Main Sector
Biotechnology - Therapeutics and Diagnostics
Subsectors
Other
Drug delivery
Small molecules
Indications
Endocrine, nutritional and metabolic diseases / endocrinology
Genitourinary system / Urology
Congenital malformations, deformations and chromosomal abnormalities / medical genetics
Products
In development: 7
Description
Syntis Bio operates as a late-stage preclinical company intended to develop a new class of therapy. The company's drug uses novel formulations for oral therapies that target specific tissues, enabling users to increase bioavailability. Their core technology, SYNT™, utilizes mussel-inspired polymer chemistry to create a temporary, biocompatible coating on the small intestine's lining.
